|
| This article is part of the supplement: 6th Global Arthritis Research Network (GARN) MeetingPoster presentationTolerogenic dendritic cells differentially modulate naïve and memory CD4+ T cellsClinical Immunotherapy Group, Department of Rheumatology, Newcastle University, UK Zurich, Switzerland. 10–13 May 2007 Arthritis Research & Therapy 2007, 9(Suppl 3):P10doi:10.1186/ar2236 The electronic version of this abstract is the complete one and can be found online at: http://arthritis-research.com/content/9/S3/P10
© 2007 BioMed Central Ltd BackgroundDendritic cells (DC) can be alternatively activated to induce tolerogenic DC, making them a promising therapy for autoimmunity. Because naïve and memory T cells have different requirements for tolerisation, we tested the modulatory activity of tolerogenic DC on both subsets of T cells. MethodsHuman monocyte-derived DC were matured with lipopolysaccharide (LPS-DC) or treated with dexamethasone, vitamin D3 and lipopolysaccharide (LPS-DexD3 DC) to obtain tolerogenic DC. DC were cocultured with allogeneic naïve or memory CD4+ T cells. Primed T cells were rested and restimulated with LPS-DC or CD3/CD28 beads. Results and conclusionsLPS-DexD3 DC have reduced stimulatory capacity for both naïve and memory T cells. However, restimulation of T cells revealed a distinct difference between naïve and memory T cells that had been primed by LPS-DexD3 DC. Naïve T cells did not become anergic but were skewed to a regulatory phenotype (low IFNγ and high IL-10 production), whereas memory T cells were rendered hyporesponsive, with low proliferation and cytokine production. Thus, naïve and memory T cells are differently regulated by LPS-DexD3 DC. These data have implications for the use of tolerogenic DC vaccines as immunomodulators. Have something to say? Post a comment on this article! |



on Google Scholar




